Bayer’s 58.74% Rally Hits a Summer Pause as Two Make-or-Break Dates Approach
Published on 07/26/2026 at 10:01 | Redaktion boerse-global.de
The Bayer share has been one of the best performers on the DAX over the past twelve months, surging 58.74% as a landmark US Supreme Court ruling reshaped the legal landscape around its glyphosate-based herbicide Roundup. But after that blistering run, the stock has entered a consolidation phase, slipping 4.48% over the past week to close at €46.01 on Friday — 14.6% below its 52-week high of €53.86 touched in early July.
The next few weeks will determine whether the pause turns into a renewed push toward the €60 mark or a deeper pullback below the psychologically important €50 threshold. Two events dominate the calendar: the release of second-quarter earnings on August 4 and a critical court hearing in Missouri on August 19.
Earnings Season Brings a Quiet Period Challenge
Analysts expect Bayer to report second-quarter revenue in the range of €10.69 billion to €10.73 billion, roughly flat year-on-year. Adjusted EBITDA is forecast at around €1.94 billion. JPMorgan’s Richard Vosser anticipates that management will reaffirm its 2026 full-year targets when it presents the numbers on Tuesday.
The timing is tricky. Bayer is currently in a quiet period, which prohibits the company from communicating new strategic details. That makes the August 4 earnings call the first real opportunity for investors to gauge whether operational momentum is building behind the scenes.
Should investors sell immediately? Or is it worth buying Bayer?
The Legal Calendar Shifts — But the Trend Remains Intact
The legal front has been the dominant driver of Bayer’s share price for years, and that remains the case. A hearing scheduled for July to approve a glyphosate settlement in Missouri has been pushed back to August 19. Bayer has downplayed the delay, insisting it won’t materially affect the overall process.
The bigger picture is far more favorable for the company. On June 25, the US Supreme Court ruled 7-2 that Bayer cannot be sued under state law for failing to warn about the alleged cancer risks of glyphosate — a decision that effectively dismantled one of the main legal avenues plaintiffs had used to pursue claims. The ruling followed years of protests outside the courthouse, including demonstrations by the Make America Healthy Again movement, and marks a decisive shift in the risk calculus that has weighed on the stock.
That legal victory is the primary reason Bayer shares have delivered a 58.74% return over the past twelve months. The stock has already priced in much of the relief, but the August 19 hearing will test whether the legal momentum can sustain the rally.
Debt Reduction Moves Into Focus
While investors watch the court calendar, Bayer has been quietly strengthening its balance sheet. In the second half of July, the company placed $5 billion in US dollar-denominated bonds and secured an additional €3 billion in fresh financing. Both moves are aimed at addressing the group’s hefty net financial debt, which stood at €32.5 billion at the end of the first quarter.
The bond issuance signals that management is serious about deleveraging, even as it navigates the legal overhang. For shareholders, a cleaner balance sheet reduces the risk of a dilutive capital increase and provides a stronger foundation for any future dividend restoration.
Bayer at a turning point? This analysis reveals what investors need to know now.
Technical Picture: Neutral, Not Negative
From a chart perspective, the current consolidation looks healthy rather than alarming. The relative strength index sits at 49.6 — a neutral reading that suggests the stock is neither overbought nor oversold. The share has simply taken a breather after a powerful run.
The path forward hinges on the August double-header. A strong earnings report followed by a positive outcome in Missouri could reignite the uptrend and push Bayer toward the €60 level. If both events disappoint, the consolidation below €50 is likely to extend. For now, the market is holding its breath.
Ad
Bayer Stock: New Analysis - 26 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
